Evolus—(EOLS)—completes IPO despite the FDA’s 483 citation at Daewoong’s Korea manufacturing plant (#msg-137992785), selling 5.75M* shares @$12.00—the bottom of the projected $12-14 range:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.